DUBLIN, Calif., Jan. 2 /PRNewswire/ -- Microchip Biotechnologies, Inc. (MBI) has been selected for participation in the inaugural US Army Commercialization Pilot Program. The Commercialization Pilot Program is a new program to identify SBIR firms that have Phase II projects with high transition potential to commercial products that meet high priority Army requirements. MBI was identified as one of 25 firms selected out of 529 eligible firms and 416 applicants (http://www.armysbir.com/sbir/cpp_fy08.htm). MBI has been developing a biothreat detection system under Army SBIR funding. "The acceptance of MBI by the Army to participate in the CPP is a further validation of our commitment to develop and commercialize microfluidic technologies for the protection of the combat troops and civilian populations," said Dr. Stevan Jovanovich, President and CEO of MBI.
About Microchip Biotechnologies, Inc.
Microchip Biotechnologies, Inc. is a privately-held company located in Dublin, California that is developing the Apollo next-generation fluidics platform for Life Sciences, Applied Sciences, and Diagnostics markets. The Apollo platform integrates advanced microfluidic sample preparation and analytical capabilities to produce sample-to-answer performance for DNA sequencing, biodefense, forensics, and molecular diagnostics applications. The Apollo platform incorporates MBI's proprietary BeadStorm(TM) bead-based sample preparation devices and "Microscale On-Chip" (MOV(TM)) valves, pumps, and routers on microchips. More details can be found on the Company's website: http://www.microchipbiotech.com.
CONTACT: Barney Saunders, Ph.D., Chief Commercial Officer of Microchip
Biotechnologies, Inc., +1-925-558-2028,
barney.saunders@microchipbiotech.com
Web site: http://www.microchipbiotech.com/
